✦ LIBER ✦

823 IMPACT OF PRIOR TACE/TAE ON THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FROM THE ASIA-PACIFIC REGION

✍ Scribed by W.Y. Tak; S. Yu; C.J. Tsao; T.S. Yang; J.S. Kim; S. Qin; K. Burock; J. Zou; D. Voliotis; A.L. Cheng

Book ID: 117377829
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60825-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6519 Efficacy and safety of sorafenib in

6519 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials

✍ Llovet, J.; Cheng, A.; Qin, S.; Shan, M.; Nadel, A.; Burock, K.; Forner, A.; Zou 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

807 IMPACT OF LUNG AND LYMPH NODE METAST

807 IMPACT OF LUNG AND LYMPH NODE METASTASIS ON EFFICACY AND SAFETY FOLLOWING TREATMENT WITH SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA FROM THE ASIA-PACIFIC REGION

✍ H. Pan; Z. Guan; Y.K. Kang; Z. Chen; C.J. Tsao; A.L. Cheng; J.S. Kim; K. Burock; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial

✍ Ann-Lii Cheng; Zhongzhen Guan; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Su 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 553 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

## Background: Most cases of hepatocellular carcinoma occur in the asia-pacific region, where chronic hepatitis b infection is an important aetiological factor. assessing the efficacy and safety of new therapeutic options in an asia-pacific population is thus important. we did a multinational phase

994 EFFICACY AND SAFETY OF SORAFENIB IN

994 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND PRIOR ANTI-TUMOR THERAPY: A SUBANALYSIS FROM THE SHARP TRIAL

✍ P. Galle; J. Blanc; J.-L. Van Laethem; J. Marrero; M. Beaugrand; M. Moscovici; M 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 52 KB